Novanta (NOVT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Novanta reported record revenue in Q4 2025 with 9% reported growth, 2% organic growth, and 4% sequential growth, achieving $981 million in revenue for the full year, the largest in its history [5][6] - Adjusted EBITDA grew by 17% year-over-year, and Adjusted Diluted EPS increased by 20% in Q4 2025 [6][24] - Non-GAAP adjusted gross profit for Q4 was $118 million, with a gross margin of 45.5%, down from 47% in Q4 2024 [21][24] - Operating cash flow in Q4 was $9 million, significantly lower than $62 million in Q4 2024, impacted by regional manufacturing dynamics and higher inventory [25][26] Business Line Data and Key Metrics Changes - New product revenue grew over 60% for the full year, with over 80% growth in Q4, indicating strong commercial excellence and innovation investments [6][20] - The Automation Enabling Technologies segment saw a 2% year-over-year revenue growth in Q4, with bookings up 33% [28] - The Medical Solutions segment experienced a 16% year-over-year revenue growth in Q4, with advanced surgery business growing 15% [30][31] Market Data and Key Metrics Changes - Sales in medical end markets represented 53% of total sales, while advanced industrial markets accounted for 47% [20] - The precision manufacturing business saw a year-over-year revenue decline of 3% in Q4 but had double-digit growth in bookings [28][30] - The robotics and automation business grew revenues by 6% year-over-year in Q4, benefiting from demand in advanced robotic applications [28] Company Strategy and Development Direction - Novanta's long-term growth strategy focuses on high-growth end markets such as AI-driven robotics, minimally invasive surgery, and precision medicine, with a target of $4 billion incremental market opportunity by 2030 [7][9] - The company aims to drive mid-single-digit organic growth in 2026, supported by record bookings and new product launches [10][18] - Acquisitions are a key growth strategy, with a pipeline focused on mid to larger opportunities in medical technologies and embedded software [10][43] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to mid-single-digit organic growth, citing strong demand and a recovering semiconductor market [10][12] - The company anticipates a significant inventory drawdown and strong cash rebound as regional manufacturing initiatives are completed [25][26] - Management highlighted the importance of customer relationships and the ability to solve complex problems as a competitive advantage [82] Other Important Information - The company ended Q4 with gross debt of $260 million and a net cash position for the first time in over a decade [26] - Novanta's investments in intelligent RFID solutions and advanced machine vision technologies are expected to stabilize the outlook for the business [16] Q&A Session Summary Question: Can you elaborate on the sequential increase in bookings in the Automation Enabling Technologies segment? - Management noted broad-based growth across all businesses, with strong momentum in robotics and automation, particularly in precision robotics and semiconductor capital equipment [47][48] Question: What is the revenue expectation for the industrial robotics order announced previously? - Management indicated that revenue from the first phase of ramp will be modest this year, with sequential growth expected thereafter, highlighting technology leadership as a key factor [54][56] Question: How does the company reconcile strong bookings momentum with EPS growth expectations? - Management explained that the EPS growth is impacted by the recent fundraise and an all-employee equity grant, but organic growth remains strong despite these headwinds [62][63] Question: Can you provide insights on the GPU boards opportunity? - Management confirmed that they are the leading supplier for drilling AI-driven GPU boards, with strong demand expected to continue, indicating a multi-year growth trajectory [66][67] Question: Was the positive book-to-bill across all business units? - Management confirmed that all four business units had a positive book-to-bill ratio, indicating strong momentum and building backlog [71][72]